IN2012DN01209A - - Google Patents
Info
- Publication number
- IN2012DN01209A IN2012DN01209A IN1209DEN2012A IN2012DN01209A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A IN 1209DEN2012 A IN1209DEN2012 A IN 1209DEN2012A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A
- Authority
- IN
- India
- Prior art keywords
- composition
- disclosed
- treating
- disorders
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22642509P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042308 WO2011009061A1 (fr) | 2009-07-17 | 2010-07-16 | Compositions comprenant un inhibiteur de la cholinestérase pour traiter des troubles cognitifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01209A true IN2012DN01209A (fr) | 2015-04-10 |
Family
ID=42990151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1209DEN2012 IN2012DN01209A (fr) | 2009-07-17 | 2010-07-16 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110015179A1 (fr) |
| EP (1) | EP2453890B1 (fr) |
| JP (1) | JP2012533566A (fr) |
| KR (1) | KR101757003B1 (fr) |
| CN (1) | CN102497861A (fr) |
| AU (1) | AU2010273977A1 (fr) |
| BR (1) | BR112012001047A2 (fr) |
| CA (1) | CA2768356A1 (fr) |
| DK (1) | DK2453890T3 (fr) |
| ES (1) | ES2809298T3 (fr) |
| IN (1) | IN2012DN01209A (fr) |
| PT (1) | PT2453890T (fr) |
| RU (2) | RU2607946C2 (fr) |
| WO (1) | WO2011009061A1 (fr) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| WO2005072713A2 (fr) | 2004-01-27 | 2005-08-11 | The Feinstein Institute For Medical Research | Inhibiteurs de la cholinesterase pour traiter l'inflammation |
| US20070212253A1 (en) * | 2004-12-21 | 2007-09-13 | Elrod Scott A | Descenting systems and methods |
| CN101151248B (zh) | 2005-01-26 | 2012-06-20 | 阿勒根公司 | 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物 |
| CA2616858A1 (fr) * | 2005-07-27 | 2007-02-01 | Carlos Henrique Horta Lima | Preparation pharmaceutique contenant un inhibiteur de l'acetylcholinesterase et un antidepresseur ayant des proprietes bloquant la 5-ht et l'alpha-2-adrenocepteur. |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| WO2008109287A1 (fr) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Procédés de traitement de troubles cognitifs utilisant les 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, les amides d'acide 3-benzyl-3-hydroxy-2-amino-propionique et les composés apparentés |
| US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| PT2481407T (pt) * | 2007-03-06 | 2018-12-28 | Allergan Inc | Compostos para utilização no tratamento de distúrbios cognitivos |
| US20100105687A1 (en) * | 2007-03-06 | 2010-04-29 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| ES2621160T3 (es) * | 2007-07-17 | 2017-07-03 | Allergan, Inc. | Tratamiento de la ansiedad |
-
2010
- 2010-07-16 CA CA2768356A patent/CA2768356A1/fr not_active Abandoned
- 2010-07-16 WO PCT/US2010/042308 patent/WO2011009061A1/fr not_active Ceased
- 2010-07-16 KR KR1020127003979A patent/KR101757003B1/ko active Active
- 2010-07-16 ES ES10735143T patent/ES2809298T3/es active Active
- 2010-07-16 AU AU2010273977A patent/AU2010273977A1/en not_active Abandoned
- 2010-07-16 US US12/838,019 patent/US20110015179A1/en not_active Abandoned
- 2010-07-16 RU RU2012103401A patent/RU2607946C2/ru not_active Application Discontinuation
- 2010-07-16 PT PT107351439T patent/PT2453890T/pt unknown
- 2010-07-16 CN CN201080041187XA patent/CN102497861A/zh active Pending
- 2010-07-16 JP JP2012520814A patent/JP2012533566A/ja active Pending
- 2010-07-16 EP EP10735143.9A patent/EP2453890B1/fr active Active
- 2010-07-16 IN IN1209DEN2012 patent/IN2012DN01209A/en unknown
- 2010-07-16 DK DK10735143.9T patent/DK2453890T3/da active
- 2010-07-16 RU RU2016151986A patent/RU2016151986A/ru not_active Application Discontinuation
- 2010-07-16 BR BR112012001047A patent/BR112012001047A2/pt not_active IP Right Cessation
-
2012
- 2012-10-11 US US13/649,404 patent/US9492543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016151986A (ru) | 2018-12-19 |
| RU2012103401A (ru) | 2013-08-27 |
| AU2010273977A1 (en) | 2012-02-02 |
| ES2809298T3 (es) | 2021-03-03 |
| DK2453890T3 (da) | 2020-08-17 |
| PT2453890T (pt) | 2020-08-25 |
| BR112012001047A2 (pt) | 2019-09-24 |
| KR101757003B1 (ko) | 2017-07-11 |
| EP2453890B1 (fr) | 2020-05-27 |
| US20130040938A1 (en) | 2013-02-14 |
| JP2012533566A (ja) | 2012-12-27 |
| US20110015179A1 (en) | 2011-01-20 |
| RU2607946C2 (ru) | 2017-01-11 |
| KR20120090029A (ko) | 2012-08-16 |
| US9492543B2 (en) | 2016-11-15 |
| CN102497861A (zh) | 2012-06-13 |
| EP2453890A1 (fr) | 2012-05-23 |
| CA2768356A1 (fr) | 2011-01-20 |
| WO2011009061A1 (fr) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500975A1 (en) | Nampt and rock inhibitors | |
| IN2012DN03883A (fr) | ||
| JO2892B1 (en) | CYP inhibitors 17 | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| EA201200373A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| MX2012004780A (es) | Inhibidores de akt. | |
| MY152271A (en) | Novel compounds that are erk inhibitors | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| WO2011014795A3 (fr) | Composés et compositions pouvant servir d'inhibiteurs de la kinase syk | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| GEP20125708B (en) | Hydroxamate-based inhibitors of deacetylases b | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
| IN2012DN03182A (fr) | ||
| IN2012DN01273A (fr) | ||
| AU2011326186A8 (en) | Selective glycosidase inhibitors and uses thereof | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| PH12016502534A1 (en) | Azaquinazoline carboxamide derivatives | |
| IN2012DN03846A (fr) | ||
| WO2011088160A3 (fr) | Nouveaux inhibiteurs de cyp17 | |
| WO2010077730A3 (fr) | Inhibiteurs indanones de l'acétylcholinestérase | |
| UA109793C2 (uk) | Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс) |